IL13 and asthma: The observation that CS markedly reduces IL‐13‐induced CLCA1 and POSTN expression, which does not recover after CS cessation, is an important finding for biomarker‐guided therapy in asthma since especially periostin is considered as an emerging biomarker for Th2 inflammation.